#None #financial report #SOPHiA GENETICS #AI-driven medicine

Financial Performance Overview of SOPHiA GENETICS in 2025

SOPHiA GENETICS, a leading entity in AI-driven precision medicine, recently released its financial results for the fourth quarter and full year of 2025. The organization highlighted a remarkable revenue increase along with strategic advancements in its operational capabilities, marking a significant year in its corporate journey.

Fourth Quarter Highlights

For the quarter ending December 31, 2025, SOPHiA GENETICS reported a revenue of $21.7 million. This figure represents a substantial 22% growth compared to the same quarter of the previous year. The company's gross margin also exhibited strong performance, standing at 67.7% on a reported basis and 73.9% when adjusted, showing consistency in maintaining profitability despite operational costs. However, the company recorded a net loss of $19.2 million, illustrating a 27% year-over-year increase in losses, attributed to expanded operational expenses aimed at scaling the business.

Yearly Performance Indicators

Across the entire year of 2025, SOPHiA GENETICS achieved a total revenue of $77.3 million, achieving a 19% increase relative to the previous year. The growth in revenue is a testament to the efficacy and acceptance of their proprietary SOPHiA DDM™ platform within the healthcare sector. Despite this increase, the total net loss escalated to $79.0 million, marking a 26% rise from 2024, driven by higher investments in research and technology advancements.

The CEO of SOPHiA GENETICS, Jurgi Camblong, expressed confidence in the company's growth trajectory, emphasizing the consistent demand for their services. He noted, "Our growth momentum continues to accelerate... and we are now extending partnerships, enhancing capabilities, and executing strategies that are set to propel us further."

Business Developments and Strategic Collaborations

SOPHiA GENETICS has been proactive in expanding its client base, marking the signing of 124 new core genomic customers in 2025, which is a significant uplift from 92 in 2024. This includes key partnerships with large integrated health systems in the United States, aimed at utilizing their platform for analyzing substantial volumes of patients. The partnerships are poised to increase usage significantly, with projections indicating an addition of 60,000 analyses annually from these systems.

In addition to the core business growth, the company has started to gain traction in the Liquid Biopsy segment, performing over 7,500 analyses in 2025 alone. Such initiatives spearheaded by new applications underscore SOPHiA's commitment to innovation in the rapidly evolving healthcare landscape.

Financial Outlook for 2026

Looking ahead, SOPHiA GENETICS has set an optimistic financial outlook for 2026, forecasting revenue between $92 million and $94 million, equivalent to a projected growth of 20% to 22% from 2025 figures. The leadership team remains focused on continued expansion of their operations in the U.S., as well as enhancing their services in the area of Liquid Biopsy applications. Camblong added that the operational leverage is expected to improve, enabling the company to approach adjusted EBITDA breakeven by the end of 2026.

With their groundbreaking advancements and solidifying position in AI-driven precision medicine, SOPHiA GENETICS continues to demonstrate resilience and growth potential as they ascend in the competitive landscape of healthcare technology. Investors and stakeholders are keenly awaiting further developments as the company continues to push the boundaries of technology and medicine.

Conclusion

As SOPHiA GENETICS concludes a transformative year, the company remains on a trajectory aimed at meeting the increasing demands for precision medicine solutions globally. With its established AI platform and expanding client partnerships, SOPHiA GENETICS is well-positioned for future growth in the healthcare sector, laying down an optimistic foundation for ongoing success in the years to come.